Skip to main content

Table 3 Studies of immunotherapy in patients with EGFR ex20ins NSCLC

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Treatment (reference)

N

Line

ORR (%)

mPFS (months)

mOS (months)

ICI (monotherapy or combination therapy) [43]

15

≥1

6.7

2.0

5.3

ICI monotherapy [44]

11

1

9.1

11.0

3.1

ICI + platinum agent [44]

16

1

18.8

11.3

4.5

ICI monotherapy [44]

32

≥2

3.1

8.1

2.3

ICI + platinum agent [44]

20

≥2

5

7.1

2.2